Cancer Research and Therapy

Dr. Ashok Srivastava is Chief Executive Officer and Chief Medical Officer of Cure Pharmaceuticals, and ClinFomatrix Oncology CRO, He was founder, Chief Executive Officer and Chief Medical Officer of CareBeyond - A Radiation Therapy Cancer Center, New Jersey. USA. He has more than 15 years of experience in drug development, medical affairs and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase 1 – 4, and marketing commercialization of Hematology, Oncology and radio-immuno-oncology drugs in USA, EU and Japan. He is leader in Cancer Drug Development Worldwide large and complex Phase 3 Clinical Trials. He contributed to 21-INDs and 7-NDAs of Cancer Drugs, acquisition /merger of company and drug for more than $900 million. He received his clinical, medical training & worked at renowned medical centers and pharmaceutical institutions worldwide at various executive leadership positions; Walter Reed Army Institute of Research and Medical Center, Daiichi Pharmaceuticals, Sumitomo Pharmaceuticals, Pharmacia, Pfizer, Eisai Oncology, Spectrum Pharmaceuticals and Taiho Oncology. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive for metastatic breast cancer patients and Latuda (Lurasidone) for schizophrenia. He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous National & International prestigious medical awards and recognitions from United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor to Poniard Pharmaceutical for small cell lung cancer and Taiho Oncology in USA, EU and India. Dr. Srivastava is member of numerous prestigious organizations; America’s Top Oncologist of the years 2017, Breast Cancer Foundation, Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer. Dr. Srivastava is a strategic medical advisor and Board Member to several pharma in USA for clinical, regulatory and supervises cancer drug development. Recently Dr. Srivastava was awarded membership of Japan External Trade Organization, USA. Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of Oncology, hematology, immuno-oncology and built global drug safety and pharmacovigilance companies in USA, and India. Dr. Srivastava was invited as an honorable speaker at drug safety & Pharmacovigilance congress in London, UK, India and Washington, DC, USA in 2017. Dr. Srivastava brought 2 cancer drugs & a vaccine in global market for approximately 3 – 3.5 billion $ in global sales. He serves as board of directors for oncology pharma companies in USA. Talk to Us Speak directly to one of our conference representatives by calling. +44 8000 148923 Mail Us E-mail us your questions about the conference. We will respond to your questions. contact@euros

Oncology

Nik received his BSc (Biochemistry & Genetics) and his PhD at the University of Leeds. This was followed by a post-doctoral fellowship at the Cancer Research UK Centre (St James’ Hospital, Leeds) and an EPSRC-funded fellowship in the Jack Birch Unit of Molecular Carcinogenesis (University of York). Following that, he moved to the Department of Biological Sciences at the University of Huddersfield where he is currently a Reader (Associate Professor) in Cell Biology.

Nik’s research focuses on understanding how the process of epithelial cancer development influences proliferation/growth, differentiation and particularly cell responses to death signals triggered by members of the TNF Receptor (TNFR) family of proteins. The aim is to use such knowledge to design novel, tumour-specific anticancer therapies. Currently he is developing a novel platform of cancer therapeutics based on the TNFR family (ThanatoCure™). His skin-related research involves using biological models to explore, at the cellular and molecular level, the underlying mechanisms of defective wound healing and chemotherapy-induced alopecia. This will permit the improvement of existing medical devices and design of novel technologies to provide improved therapeutic intervention strategies. Nik has a major industrial collaboration on skin-related research with Paxman (http://paxman-coolers.com).

Khalid Matin, M.D., F.A.C.P., has been appointed as a medical director of community oncology and clinical research affiliations at VCU Massey Cancer Center and an associate professor in the Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine, at the VCU School of Medicine, effective July 15, 2013. Most recently, Matin was director of community oncology and associate professor of oncology at Roswell Park Cancer Institute in Buffalo, New York. He was also an attending physician at Roswell’s satellite facility in Amherst, NY. Prior to his roles at Roswell, Matin was a medical oncologist at the Cancer Center of Montgomery, Alabama, which is part of the Southeast Cancer Network; a clinical assistant professor at the University of Alabama in Birmingham and University of Pittsburgh Cancer Institute in Pennsylvania; and attending physician in hematology-oncology at the Veterans Affairs Medical Center in Pittsburgh. A board-certified medical oncologist and clinical researcher, Matin is an expert in the study and treatment of gastrointestinal (GI) cancers. He has developed several clinical trials for GI cancers, and he has served as the principal investigator and co-investigator on various colorectal and lung cancer trials.

Matin is an expert in the study and treatment of gastrointestinal (GI) cancers. He has developed several clinical trials for GI cancers and lung cancer.

Oliver Micke has completed his PhD at the age of 35 years from Muenster University Hospital in 2006. He is head of the Head of the department for radiotherapy and radiation oncology at the Franziskus Hospital Bielefeld since 2006. In addition, he is the medical director of Franziskus Hospital Bielefeld, a premier teaching hospital of the Medical University of Hanover (MHH). He has published more than 200 papers in reputed national and international journals and has been serving as a reviewer as well as an editorial board member of repute.

Radiation Oncology, Breast Cancer, Prostate Cancer, Modern and Advanced Radiotherapy Treatment Techniques, Reirradiation, Cytoprotection, Radiotherapy for Rare Diseases, Radiotherapy for Benign Disorders, Complementary and Alternative Medicine, Selenium, Magnesium, Trace Elements and Electrolytes

Dr Adhip P.N. Majumdar received his MS and PhD degrees from the University of London, England, and D.Sc (Doctor of Science) degree in Gastroenterology from the University of Aarhus, Denmark. Dr. Majumdar has been a Professor at Wayne State University since 1992 and holds the post of Senior Research Career Scientist at the Detroit VA Medical Center. He has published over 200 original scientific articles and a multitude of book chapters/review articles. Dr.Majumdar's lab is particularly interested in elucidating the patho-physiology of age-related changes in the GI mucosa specifically those that lead to malignancy. To this end, Dr Majumdar has been investigating the role of pluripotent, self-renewing CSCs in the development and progression of GI malignancies. Dr Majumdar has been funded by the VA and NIH.

Role of pluripotent, self-renewing CSCs in the development and progression of GI malignancies.

Dr Cihangir Akyol graduated from Gazi University School of Medicine in 2002. He completed general surgery residency program at Ankara University School of Medicine in 2008. During his residency, he attended “Upper and lower gastrointestinal endoscopy” program in Ankara University. Dr Akyol completed his mandatory government service at Sungurlu State Hospital between September 2008 and June 2010 as the Chief of Surgery and Emergency Departments. In June 2010 he started working at Ankara University Surgery Department as a consultant surgeon. In 2014 he was granted a travel award from the Turkish Society of Colon and Rectal Surgery to visit the Cleveland Clinic Digestive Disease Institute Department of Colorectal Surgery in Ohio, the USA for 3 months. During his visit, he completed robotic surgery courses on animal models. He has been promoted to associate professor of surgery in the section of colorectal surgery, at Ankara University School of Medicine. He is also board certified by European Society of Colo-proctology since 2016. His main interests are colorectal surgery and minimally invasive surgery including both laparoscopic and robotic surgery. His main career objective is to develop himself as a lifelong proactive learner- through following up the latest advances in colorectal surgery, minimally invasive surgery, and gastrointestinal endoscopy, besides active involvement in experimental research for promotion of the surgical knowledge and skills.

His main interests are colorectal surgery and minimally invasive surgery including both laparoscopic and robotic surgery.

Professor Ioannis S. Patrikios received his BSc degree in Pre-Medical studies/Biochemistry from the City College of the City University of NY. He completed his PhD studies in 1994, specialized on Immunology and Lipids/Lipidomics and post-doctoral studies specialization in Medical Biochemistry at the City College of NY, next to the world-known Professor CS Russell. Professor Patrikios went through several different fellowships including research specializations /collaborations with different high reputation institutions including, Mount Sinai NY and was awarded advanced Immunology specialization courses at Scuola Superiore d'Immunologia Ruggero Ceppellini, Italy. He served and continues to serve as a Research Scientific Consultant for Industry and higher education. His broad research interests include studies of new therapeutic approaches of chronic diseases by the use of Systems Medicine, through Systems Biology and Nutritional Systems Biology; Lipid Hemagglutinins, Lectins, Immunology and the use of novel interventions against Metastatic Tumor Cells. As from 2004, Professor Patrikios got involved in the research of innovative, pioneer, holistic therapeutic approaches for chronic multifactorial Neurodegenerative diseases, specifically of Multiple Sclerosis. He is affiliated as a Graduate Studies Mentor with the Institute of Brain Chemistry of London. During the last decade he has obtained many competitive research grants, participated in several different collaborative European scientific research-projects and he organized several large European Consortium Platforms for research and Clinical Trials. His 2002 research findings on the effect of frying oils as human hemagglutinins got an international interest; and have been discussed by several different National Food and Drug Administrations, including UK, and through articles in high impact Magazines such as the New Scientist. He has lately been honored with the tittle of a fellow and member of the advisory board of the Forensic Pathology Academy of London. He has been appointed as a reviewer and editor of several international scientific journals in the field of Medicine, Med-Biochemistry, Pharmaceuticals-Therapeutics and Neurology and as a reviewer for research grants. He is the solid author of University Books in Biochemistry and Medical Biochemistry and he has authored numerous peer-reviewed, limited co-authored original publications, in high impact factor scientific journals. Professor Patrikios is a member of several International associations and bodies including Sigma Xi. He is the chief scientific investigator of the team which lately invented and patented the nutraceutical formula PLP10 as a new therapeutic intervention for multiple sclerosis. He is the co-founder and Director of PALUPA Medical Ltd (a research and innovation company), that performed and successfully completed the phase II clinical trial for PLP10. Now he is the scientific coordinator of the “MINERAL” phase III multicenter clinical trial for PLP10. At present he is a Professor, Faculty of Medicine and the Chairman of the School of Medicine of the European University of Cyprus and affiliated as a research collaborator at the Cyprus Institute of Neurology and Genetics.

His 2002 research findings on the effect of frying oils as human hemagglutinins got an international interest, and have been discussed by several different National Food and Drug Administrations